Developer docs
API playgroundTry for free, no card

Search company profiles

Benitec Biopharma

Full company profile

uuid0004wdw

Namestring
Benitec Biopharma
Legal namestring
Benitec Biopharma Inc.
Websiteurl
benitec.com
Company typeenum
Public
Founded yearint
1995
Descriptiontext

Benitec Biopharma Inc. is a clinical-stage biotechnology company developing genetic medicines based on its proprietary DNA-directed RNA interference (ddRNAi) platform. The 'Silence and Replace' approach combines RNA interference-mediated gene silencing with AAV-based gene therapy to simultaneously silence mutated disease-causing genes and replace them with wild-type genes following a single administration. The company's lead product candidate, BB-301, is an AAV-based gene therapy in Phase 1b/2a clinical development for Oculopharyngeal Muscular Dystrophy (OPMD), a rare genetic muscle disorder affecting approximately 15,000 patients across North America, Europe, and Israel that causes progressive dysphagia and muscle weakness with no currently approved therapies.

BB-301 has received FDA Orphan Drug Designation, FDA Fast Track Designation (November 2025), and EMA Orphan Drug Designation, and has demonstrated 100% response rate in Cohort 1 of its Phase 1b/2a trial with durable responses extending to 24 months and statistically significant improvements across multiple dysphagia measures. The company is headquartered in Hayward, California (re-domiciled from Australia to Delaware in April 2020), is listed on Nasdaq under ticker BNTC, and has 11-50 employees.

The company is pre-revenue with no approved products; historical revenue consisted solely of minimal licensing royalties (approximately $55-56K in FY2021 periods). Revenue model is anticipated to shift to product sales upon FDA approval of BB-301. The company has been funded through equity financings totaling approximately $169.4M since 2020, most recently a $100M public offering in November 2025, and holds $184.8M in cash as of March 2026. The go-to-market motion is enterprise/field-sales oriented for clinical-stage engagement with FDA, clinical trial sites, and academic conferences (MDA, ASGCT), with planned commercial distribution to be established upon regulatory approval.

Short descriptiontext

Benitec Biopharma is a clinical-stage biotechnology company developing BB-301, an AAV-based gene therapy using its proprietary ddRNAi 'Silence and Replace' platform to treat Oculopharyngeal Muscular Dystrophy (OPMD), a rare genetic muscle disorder with no approved therapies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersHayward, United States
HQ citystring
Hayward
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
gene therapy, RNA interference, rare disease therapeutics, DNA-directed RNAi, AAV gene therapy
Industry3 codes
PRIMARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAIAIAA
Genetic & Genomic Rare Disease Therapeutics
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAAACAH
Neurology/CNS Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Gene Therapy Biopharmaceuticals
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Gene Therapy Development
TypeLicensing Royalties
Description

Pre-revenue clinical-stage biotechnology company. No products approved for commercial sale. Revenue historically from licensing fees and royalties from intellectual property licensing arrangements.

globenewswire.com
2Future Product Revenue
TypeOne Time License
Description

Anticipated revenue from commercialization of BB-301 upon FDA approval for OPMD treatment. Company maintains robust cash position ($184.8M as of March 2026) to fund development through pivotal study completion.

finance.yahoo.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Benitec Biopharma is a clinical-stage biotechnology company developing BB-301, an AAV-based gene therapy candidate for Oculopharyngeal Muscular Dystrophy (OPMD) using its proprietary DNA-directed RNA interference (ddRNAi) 'Silence and Replace' platform. The therapy combines gene silencing with wild-type gene replacement to address chronic and life-threatening genetic diseases with no approved treatments. The company has no products approved for commercial sale and currently derives revenue from licensing its intellectual property.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 100% response rate in Cohort 1 (6 patients) with statistically significant responses across multiple dysphagia measures
+4 more records
Product overview1 text field

Benitec Biopharma is a clinical-stage biotechnology company developing genetic medicines using its proprietary DNA-directed RNA interference (ddRNAi) 'Silence and Replace' platform. The company's lead product candidate is BB-301, an AAV-based gene therapy for Oculopharyngeal Muscular Dystrophy (OPMD) that combines gene silencing with wild-type gene replacement. BB-301 is currently in Phase 1b/2a clinical trials and has received Orphan Drug Designation from both FDA and EMA, plus FDA Fast Track Designation. The company operates as a single-segment biopharmaceutical development organization with no external API or integration offerings.

Product and service2 records
1BB-301
CategoryGene Therapy
Description

BB-301 is an AAV-based gene therapy candidate for Oculopharyngeal Muscular Dystrophy (OPMD) using a proprietary 'Silence and Replace' DNA-directed RNA interference (ddRNAi) platform. It silences mutated disease-causing genes and replaces them with wild-type genes to restore function in diseased cells. Currently in Phase 1b/2a clinical trials.

2ddRNAi Platform
CategoryTechnology Platform
Description

DNA-directed RNA interference (ddRNAi) technology platform combining RNA interference with gene therapy to create medicines enabling sustained silencing of disease-causing genes following a single administration. The platform supports the company's 'Silence and Replace' therapeutic approach.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Regenxbio is an established AAV gene therapy platform company whose NAV Technology underpins multiple approved and clinical-stage rare-disease gene therapies. Comparable as an AAV platform incumbent in the same modality space, though it operates at greater scale and across many more indications than Benitec.

TypeDirect peer
Description

Sarepta is the leading commercial-stage gene therapy company for Duchenne muscular dystrophy (DMD), with Elevidys approved for DMD and a deep pipeline of AAV-based treatments. It is the closest direct peer to Benitec given shared modality (AAV gene therapy), overlapping disease space (rare inherited muscular dystrophies), and shared regulatory pathway (Orphan Drug, accelerated approval).

TypeDirect peer
Description

uniQure is a clinical-to-commercial gene therapy company developing AAV-based therapies for rare diseases including hemophilia B and Huntington's disease. Comparable as a small-cap pure-play AAV gene therapy developer targeting rare monogenic diseases via a single-administration modality.

TypeDirect peer
Description

Capricor Therapeutics is a clinical-stage biotechnology company developing cell and gene therapy candidates for Duchenne muscular dystrophy. Directly comparable to Benitec as a small-cap rare-disease developer targeting muscular dystrophy with an advanced modality and similar regulatory positioning.

TypeDirect peer
Description

Abeona Therapeutics is a clinical-stage gene therapy company developing AAV-based treatments for rare diseases including recessive dystrophic epidermolysis bullosa. Directly comparable as a small-cap clinical-stage AAV gene therapy developer targeting a single rare monogenic disease with FDA Orphan Drug Designation.

TypeEmerging player
Description

Voyager Therapeutics is a clinical-stage gene therapy company developing AAV-based treatments for CNS and rare neurological diseases using a proprietary capsid platform. Comparable as an emerging AAV gene therapy developer focused on rare monogenic indications, though its CNS focus differs from Benitec's muscular indication.

TypeDirect peer
Description

Solid Biosciences is a clinical-stage gene therapy company developing AAV-based treatments for Duchenne muscular dystrophy and other rare neuromuscular diseases. Directly comparable to Benitec in target indication family (rare muscular dystrophy), modality (AAV gene therapy), and clinical-stage development profile.

TypeDirect peer
Description

Krystal Biotech is a commercial-stage gene therapy company with Vyjuvek approved for the rare skin disease dystrophic epidermolysis bullosa. Directly comparable to Benitec as a small-cap AAV-delivered gene therapy developer focused on a single rare monogenic disease, with a similar regulatory and commercial pathway.

TypeBroad incumbent
Description

Alnylam is the established commercial-stage leader in RNA interference (RNAi) therapeutics, with multiple approved siRNA-based drugs for rare genetic diseases. Highly relevant as the dominant incumbent in the underlying RNAi technology that Benitec's ddRNAi platform builds upon, although Alnylam uses siRNA rather than AAV delivery.

TypeBroad incumbent
Description

Pfizer is a large pharmaceutical incumbent that markets Beqvez, an FDA-approved AAV gene therapy for adult hemophilia B, and has historical programs in DMD gene therapy. Comparable as a broad incumbent in the AAV gene therapy space targeting rare monogenic diseases, though operating at vastly greater scale than Benitec.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries7 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Benitec Biopharma

Gene Therapy Biopharmaceuticalsbenitec.com

Benitec Biopharma is a clinical-stage biotechnology company developing BB-301, an AAV-based gene therapy using its proprietary ddRNAi 'Silence and Replace' platform to treat Oculopharyngeal Muscular Dystrophy (OPMD), a rare genetic muscle disorder with no approved therapies.

What Benitec Biopharma does

Benitec Biopharma Inc. is a clinical-stage biotechnology company developing genetic medicines based on its proprietary DNA-directed RNA interference (ddRNAi) platform. The 'Silence and Replace' approach combines RNA interference-mediated gene silencing with AAV-based gene therapy to simultaneously silence mutated disease-causing genes and replace them with wild-type genes following a single administration. The company's lead product candidate, BB-301, is an AAV-based gene therapy in Phase 1b/2a clinical development for Oculopharyngeal Muscular Dystrophy (OPMD), a rare genetic muscle disorder affecting approximately 15,000 patients across North America, Europe, and Israel that causes progressive dysphagia and muscle weakness with no currently approved therapies.

BB-301 has received FDA Orphan Drug Designation, FDA Fast Track Designation (November 2025), and EMA Orphan Drug Designation, and has demonstrated 100% response rate in Cohort 1 of its Phase 1b/2a trial with durable responses extending to 24 months and statistically significant improvements across multiple dysphagia measures. The company is headquartered in Hayward, California (re-domiciled from Australia to Delaware in April 2020), is listed on Nasdaq under ticker BNTC, and has 11-50 employees.

The company is pre-revenue with no approved products; historical revenue consisted solely of minimal licensing royalties (approximately $55-56K in FY2021 periods). Revenue model is anticipated to shift to product sales upon FDA approval of BB-301. The company has been funded through equity financings totaling approximately $169.4M since 2020, most recently a $100M public offering in November 2025, and holds $184.8M in cash as of March 2026. The go-to-market motion is enterprise/field-sales oriented for clinical-stage engagement with FDA, clinical trial sites, and academic conferences (MDA, ASGCT), with planned commercial distribution to be established upon regulatory approval.

Benitec Biopharma firmographics

Firmographics
Name
Benitec Biopharma
Legal name
Benitec Biopharma Inc.
Website
https://benitec.com
Company type
Public
Founded year
1995
Operating status
Operating
Headcount range
11–50 employees
Short description
Benitec Biopharma is a clinical-stage biotechnology company developing BB-301, an AAV-based gene therapy using its proprietary ddRNAi 'Silence and Replace' platform to treat Oculopharyngeal Muscular Dystrophy (OPMD), a rare genetic muscle disorder with no approved therapies.
Ownership category
akta.pro rank

Benitec Biopharma industry classification

Industry
Product category
Gene Therapy Biopharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAIAIAA
Genetic & Genomic Rare Disease Therapeutics
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAAACAH
Neurology/CNS Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • Gene therapy
  • RNA interference
  • Rare disease therapeutics
  • DNA-directed RNAi
  • AAV gene therapy

Where Benitec Biopharma is headquartered

Location

Headquarters

HQ city
Hayward
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Benitec Biopharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Gene Therapy Development: Pre-revenue clinical-stage biotechnology company. No products approved for commercial sale. Revenue historically from licensing fees and royalties from intellectual property licensing arrangements.
  2. Future Product Revenue: Anticipated revenue from commercialization of BB-301 upon FDA approval for OPMD treatment. Company maintains robust cash position ($184.8M as of March 2026) to fund development through pivotal study completion.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Benitec Biopharma product offering

Product offering

Core offering

Benitec Biopharma is a clinical-stage biotechnology company developing BB-301, an AAV-based gene therapy candidate for Oculopharyngeal Muscular Dystrophy (OPMD) using its proprietary DNA-directed RNA interference (ddRNAi) 'Silence and Replace' platform. The therapy combines gene silencing with wild-type gene replacement to address chronic and life-threatening genetic diseases with no approved treatments. The company has no products approved for commercial sale and currently derives revenue from licensing its intellectual property.

Product overview

Benitec Biopharma is a clinical-stage biotechnology company developing genetic medicines using its proprietary DNA-directed RNA interference (ddRNAi) 'Silence and Replace' platform. The company's lead product candidate is BB-301, an AAV-based gene therapy for Oculopharyngeal Muscular Dystrophy (OPMD) that combines gene silencing with wild-type gene replacement. BB-301 is currently in Phase 1b/2a clinical trials and has received Orphan Drug Designation from both FDA and EMA, plus FDA Fast Track Designation. The company operates as a single-segment biopharmaceutical development organization with no external API or integration offerings.

Differentiator

Problem solved

Functional benefit

Products and services

  • BB-301 BB-301 is an AAV-based gene therapy candidate for Oculopharyngeal Muscular Dystrophy (OPMD) using a proprietary 'Silence and Replace' DNA-directed RNA interference (ddRNAi) platform. It silences mutated disease-causing genes and replaces them with wild-type genes to restore function in diseased cells. Currently in Phase 1b/2a clinical trials.
  • ddRNAi Platform DNA-directed RNA interference (ddRNAi) technology platform combining RNA interference with gene therapy to create medicines enabling sustained silencing of disease-causing genes following a single administration. The platform supports the company's 'Silence and Replace' therapeutic approach.

Quantifiable outcome

  • 100% response rate in Cohort 1 (6 patients) with statistically significant responses across multiple dysphagia measures
  • +4 more outcomes

Companies that use Benitec Biopharma

Customer profile

Segments1 record

Ideal customer profiles2 records

Benitec Biopharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Benitec Biopharma partnerships and signals

Strategic signal

Scale indicators9 records

Recent moves7 records

Expansion highlights4 records

Benitec Biopharma competitors and assessment

Company assessment

Broad incumbents

  • Regenxbio: Regenxbio is an established AAV gene therapy platform company whose NAV Technology underpins multiple approved and clinical-stage rare-disease gene therapies. Comparable as an AAV platform incumbent in the same modality space, though it operates at greater scale and across many more indications than Benitec.
  • Alnylam Pharmaceuticals: Alnylam is the established commercial-stage leader in RNA interference (RNAi) therapeutics, with multiple approved siRNA-based drugs for rare genetic diseases. Highly relevant as the dominant incumbent in the underlying RNAi technology that Benitec's ddRNAi platform builds upon, although Alnylam uses siRNA rather than AAV delivery.
  • Pfizer: Pfizer is a large pharmaceutical incumbent that markets Beqvez, an FDA-approved AAV gene therapy for adult hemophilia B, and has historical programs in DMD gene therapy. Comparable as a broad incumbent in the AAV gene therapy space targeting rare monogenic diseases, though operating at vastly greater scale than Benitec.

Direct peers

  • Sarepta Therapeutics: Sarepta is the leading commercial-stage gene therapy company for Duchenne muscular dystrophy (DMD), with Elevidys approved for DMD and a deep pipeline of AAV-based treatments. It is the closest direct peer to Benitec given shared modality (AAV gene therapy), overlapping disease space (rare inherited muscular dystrophies), and shared regulatory pathway (Orphan Drug, accelerated approval).
  • uniQure: uniQure is a clinical-to-commercial gene therapy company developing AAV-based therapies for rare diseases including hemophilia B and Huntington's disease. Comparable as a small-cap pure-play AAV gene therapy developer targeting rare monogenic diseases via a single-administration modality.
  • Capricor Therapeutics: Capricor Therapeutics is a clinical-stage biotechnology company developing cell and gene therapy candidates for Duchenne muscular dystrophy. Directly comparable to Benitec as a small-cap rare-disease developer targeting muscular dystrophy with an advanced modality and similar regulatory positioning.
  • Abeona Therapeutics: Abeona Therapeutics is a clinical-stage gene therapy company developing AAV-based treatments for rare diseases including recessive dystrophic epidermolysis bullosa. Directly comparable as a small-cap clinical-stage AAV gene therapy developer targeting a single rare monogenic disease with FDA Orphan Drug Designation.
  • Solid Biosciences: Solid Biosciences is a clinical-stage gene therapy company developing AAV-based treatments for Duchenne muscular dystrophy and other rare neuromuscular diseases. Directly comparable to Benitec in target indication family (rare muscular dystrophy), modality (AAV gene therapy), and clinical-stage development profile.
  • Krystal Biotech: Krystal Biotech is a commercial-stage gene therapy company with Vyjuvek approved for the rare skin disease dystrophic epidermolysis bullosa. Directly comparable to Benitec as a small-cap AAV-delivered gene therapy developer focused on a single rare monogenic disease, with a similar regulatory and commercial pathway.

Emerging players

  • Voyager Therapeutics: Voyager Therapeutics is a clinical-stage gene therapy company developing AAV-based treatments for CNS and rare neurological diseases using a proprietary capsid platform. Comparable as an emerging AAV gene therapy developer focused on rare monogenic indications, though its CNS focus differs from Benitec's muscular indication.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Benitec Biopharma social profiles

Digital presence

Benitec Biopharma compliance and trust

Trust signal

Compliance3 records

Benitec Biopharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Benitec Biopharma leadership team

Management profile

Number of profiles

Profiles7 records

Benitec Biopharma subsidiaries and ownership

Company hierarchy

Subsidiaries7 records

Benitec Biopharma funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Benitec Biopharma M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Benitec Biopharma

What does Benitec Biopharma do?

Benitec Biopharma is a clinical-stage biotechnology company developing BB-301, an AAV-based gene therapy candidate for Oculopharyngeal Muscular Dystrophy (OPMD) using its proprietary DNA-directed RNA interference (ddRNAi) 'Silence and Replace' platform. The therapy combines gene silencing with wild-type gene replacement to address chronic and life-threatening genetic diseases with no approved treatments. The company has no products approved for commercial sale and currently derives revenue from licensing its intellectual property.

Is Benitec Biopharma a public or private company?

Benitec Biopharma is a public company. It is classified as public and is currently operating.

When was Benitec Biopharma founded?

Benitec Biopharma was founded in 1995. It employs 11 to 50 people.

Where is Benitec Biopharma based?

Benitec Biopharma is headquartered in Hayward, United States, in the North America region.

How does Benitec Biopharma make money?

Two revenue lines are on record. Gene Therapy Development is the primary driver. The others are future Product Revenue.

Who are Benitec Biopharma's main competitors?

Broad incumbents on record are Regenxbio, Alnylam Pharmaceuticals and Pfizer. Direct peers are Sarepta Therapeutics, uniQure, Capricor Therapeutics, Abeona Therapeutics, Solid Biosciences and Krystal Biotech. Voyager Therapeutics is listed as an emerging player.

Does Benitec Biopharma have an API?

No public API is recorded for Benitec Biopharma.

What industry is Benitec Biopharma in?

Benitec Biopharma's product category is Gene Therapy Biopharmaceuticals. Its primary akta.pro industry code is HLAAACAE, Gene Therapy for Rare/Monogenic Diseases, with a secondary code of HLAIAIAA, Genetic & Genomic Rare Disease Therapeutics. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewLeerink Partners maintains Benitec Biopharma at Outperform, raises price target to $18.27 from $18Leerink Partners maintained Benitec Biopharma at Outperform and raised its price target to $18.27 from $18, a 1.5% increase. The target implies an upside of 102.1% from the Nov 13 close of $9.04.TradingViewWedbush maintains Benitec Biopharma at Outperform, raises price target to $20 from $17Wedbush maintained Benitec Biopharma at Outperform and raised its price target to $20 from $17, a 17.6% increase. The target implies an upside of 121.2% from the Nov 13 close of $9.04.Investing.comWedbush raises Benitec BioPharma stock price target on FDA feedbackWedbush raised its price target on Benitec BioPharma to $20 from $17, maintaining an Outperform rating. The firm increased the projected success probability of BB-301 from 50% to 65% after favorable FDA feedback on the pivotal Phase 3 plan. Benitec expects to finalize the study design in Q1 2027 and initiate it in mid-2027.TradingViewBenitec Biopharma Inc. (BNTC) Reports $12.9M Q1 Net Loss; Cash Was $176.5MBenitec Biopharma reported a Q1 FY2027 net loss of $12.9M, up from $9.0M a year earlier, with cash of $176.5M at September 30, 2026. Interim BB-301 results showed a 100% responder rate across Cohorts 1 and 2, and the pivotal study design is expected in Q1 2027.The future of tradingBenitec Biopharma Q1 net loss widens on higher R&D costsBenitec Biopharma reported a Q1 net loss of $12.9 million, wider than the prior year, driven by higher R&D spending on BB-301 for OPMD. The company ended the quarter with $176 million in cash and will change its fiscal year-end to December 31. It expects to confirm the pivotal study design in the first quarter of 2027.Quiver QuantitativeBenitec Biopharma Posts $12.9 Million First-Quarter Net Loss | BNTC Stock NewsBenitec Biopharma reported a $12.9 million net loss for fiscal Q1 2026, with $176.5 million in cash. The company disclosed interim Phase 1b/2a data for BB-301 in OPMD-related dysphagia, showing a 100% responder rate. It expects to finalize the pivotal-study design in Q1 2027 and begin the trial in mid-2027.Business & FinancialRNA Interference (Rnai) - Global Strategic Business Report: Capture The US$8 Billion 2032 Market As Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Qiagen, Benitec Biopharma, And Silence TherapeuticsThe global RNA interference market was valued at US$3.3 billion in 2025 and is projected to reach US$8 billion by 2032, a CAGR of 13.7%. The products segment is forecast to reach US$4.2 billion by 2032, while services grow at 16.7% annually.Markets DailyBenitec Biopharma (NASDAQ:BNTC) Research Coverage Started at Raymond James FinancialRaymond James Financial initiated coverage on Benitec Biopharma with an outperform rating and a $14.00 price target. The stock has a consensus rating of Moderate Buy with a $22.00 target, and the company reported a loss of $0.26 per share for the quarter. Institutional investors hold 52.19% of the stock.American Banking and Market NewsRaymond James Financial Begins Coverage on Benitec Biopharma (NASDAQ:BNTC)Raymond James Financial initiated coverage on Benitec Biopharma with an outperform rating and a $14.00 price target, implying 61.85% upside from the previous close. The stock opened at $8.65, and analysts have an average rating of Moderate Buy with a $22.00 target. The company reported a loss of $0.26 per share for the quarter.MarketBeatBenitec Biopharma (NASDAQ:BNTC) Now Covered by Raymond James FinancialRaymond James Financial began coverage of Benitec Biopharma with an outperform rating and a $14 price target, implying 58.73% upside. The stock opened at $8.82, and analysts have a consensus Moderate Buy rating with a $22 target. Institutional investors hold 52.19% of the company's stock.